156 related articles for article (PubMed ID: 28446127)
21. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
22. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
23. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.
Cerussi AE; Tanamai VW; Hsiang D; Butler J; Mehta RS; Tromberg BJ
Philos Trans A Math Phys Eng Sci; 2011 Nov; 369(1955):4512-30. PubMed ID: 22006904
[TBL] [Abstract][Full Text] [Related]
24. Assessing the future of diffuse optical imaging technologies for breast cancer management.
Tromberg BJ; Pogue BW; Paulsen KD; Yodh AG; Boas DA; Cerussi AE
Med Phys; 2008 Jun; 35(6):2443-51. PubMed ID: 18649477
[TBL] [Abstract][Full Text] [Related]
25. Effect of tamoxifen on mammographic density.
Chow CK; Venzon D; Jones EC; Premkumar A; O'Shaughnessy J; Zujewski J
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):917-21. PubMed ID: 11008909
[TBL] [Abstract][Full Text] [Related]
26. Relationship between mammographic breast density and tamoxifen in women with breast cancer.
Tiersten A; Ng YY; Pile-Spellman E; Nelsen C; Noguera-Irizarry W; Brafman R; Russo D; Troxel A; Johnson A
Breast J; 2004; 10(4):313-7. PubMed ID: 15239789
[TBL] [Abstract][Full Text] [Related]
27. Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial.
Wernli KJ; Knerr S; Li T; Leppig K; Ehrlich K; Farrell D; Gao H; Bowles EJA; Graham AL; Luta G; Jayasekera J; Mandelblatt JS; Schwartz MD; O'Neill SC
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554037
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen, mammographic density, and breast cancer prevention.
Boyd NF
J Natl Cancer Inst; 2011 May; 103(9):704-5. PubMed ID: 21487099
[No Abstract] [Full Text] [Related]
29. Tamoxifen and breast density in women at increased risk of breast cancer.
Cuzick J; Warwick J; Pinney E; Warren RM; Duffy SW
J Natl Cancer Inst; 2004 Apr; 96(8):621-8. PubMed ID: 15100340
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy.
Tran WT; Childs C; Chin L; Slodkowska E; Sannachi L; Tadayyon H; Watkins E; Wong SL; Curpen B; El Kaffas A; Al-Mahrouki A; Sadeghi-Naini A; Czarnota GJ
Oncotarget; 2016 Apr; 7(15):19762-80. PubMed ID: 26942698
[TBL] [Abstract][Full Text] [Related]
31. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.
Atkinson C; Warren R; Bingham SA; Day NE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):863-6. PubMed ID: 10548313
[TBL] [Abstract][Full Text] [Related]
32. Breast fibromatosis response to tamoxifen: dynamic MRI findings and review of the current treatment options.
Plaza MJ; Yepes M
J Radiol Case Rep; 2012 Mar; 6(3):16-23. PubMed ID: 22690287
[TBL] [Abstract][Full Text] [Related]
33. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.
Hruska CB; Hunt KN; Conners AL; Geske JR; Brandt KR; Degnim AC; Vachon CM; O'Connor MK; Rhodes DJ
Breast Cancer Res; 2019 Mar; 21(1):38. PubMed ID: 30850011
[TBL] [Abstract][Full Text] [Related]
34. Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient.
Cerussi AE; Tanamai VW; Mehta RS; Hsiang D; Butler J; Tromberg BJ
Acad Radiol; 2010 Aug; 17(8):1031-9. PubMed ID: 20542448
[TBL] [Abstract][Full Text] [Related]
35. Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial.
Leproux A; O'Sullivan TD; Cerussi A; Durkin A; Hill B; Hylton N; Yodh AG; Carp SA; Boas D; Jiang S; Paulsen KD; Pogue B; Roblyer D; Yang W; Tromberg BJ
J Biomed Opt; 2017 Dec; 22(12):121604. PubMed ID: 29389104
[TBL] [Abstract][Full Text] [Related]
36. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
37. Can mammographic densities predict effects of tamoxifen on the breast?
Ursin G; Pike MC; Spicer DV; Porrath SA; Reitherman RW
J Natl Cancer Inst; 1996 Jan; 88(2):128-9. PubMed ID: 8537975
[No Abstract] [Full Text] [Related]
38. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
Schrading S; Schild H; Kühr M; Kuhl C
Radiology; 2014 Apr; 271(1):45-55. PubMed ID: 24475835
[TBL] [Abstract][Full Text] [Related]
39. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
Knight JA; Blackmore KM; Fan J; Malone KE; John EM; Lynch CF; Vachon CM; Bernstein L; Brooks JD; Reiner AS; Liang X; Woods M; ; Bernstein JL
Breast Cancer Res; 2018 Mar; 20(1):23. PubMed ID: 29566728
[TBL] [Abstract][Full Text] [Related]
40. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
